Literature DB >> 28527349

Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review.

Elsa Mendizábal1, Juan De León-Luis2, Natalia R Gómez-Hidalgo1, Laura Joigneau1, Pilar Pintado1, Patricia Rincón1, Virginia Ortega1, Santiago Lizarraga1.   

Abstract

OBJETIVES: Melanoma is one of the most frequent malignancies during gestation. However, oncological and perinatal management is still challenging. Our first objective is to describe the cases of pregnancy-associated melanoma (PAM) diagnosed in our centre between January-2004 and May-2015. Secondly, to perform a systematic review of the published articles analysing the maternal-perinatal outcomes of patients diagnosed with PAM. DESIGN, POPULATION AND METHODS: Obstetrical, oncological and perinatal variables were recorded in the case series. For the systematic review we include all published articles assessing the obstetric and neonatal outcomes in PAM cases in Pubmed, Web of Knowledge and Cochrane Library. The search was restricted to articles published in English, between January-2004 and May-2015. Study characteristics, oncological and maternal-perinatal variables were recorded in the systematic review.
RESULTS: Two patients were found: the first case presents a newly diagnosed metastatic melanoma at 26-weeks of gestation with fatal maternal and neonatal outcome. The second case presents a patient with metastatic melanoma who got pregnant during her treatment. For the systematic review we found 25 articles, providing data from 489 patients. Maternal-perinatal outcomes, including termination of pregnancy rates, vary depending on the country, gestational age and tumour stage at diagnosis. PAM is usually detected at advanced stages, even with metastasis affecting the placenta and the foetus.
CONCLUSIONS: When diagnosed at early stages, melanoma does not seem to alter the evolution of gestation, whereas patients with advanced stages of melanoma frequently deliver prematurely, by caesarean section, with lower neonatal weight, higher neonatal morbidity and mortality rates.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Perinatal outcome; Pregnancy associated melanoma; Systematic review

Mesh:

Year:  2017        PMID: 28527349     DOI: 10.1016/j.ejogrb.2017.04.023

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.

Authors:  Dimitrios C Ziogas; Panagiotis Diamantopoulos; Olga Benopoulou; Amalia Anastasopoulou; Dimitrios Bafaloukos; Alexander J Stratigos; John M Kirkwood; Helen Gogas
Journal:  Oncologist       Date:  2020-04-09

Review 2.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

3.  Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor.

Authors:  Megan Pagan; Heather Jinks; Mark Sewell
Journal:  Case Rep Womens Health       Date:  2019-09-05

Review 4.  Good news on the active management of pregnant cancer patients.

Authors:  Susan M Folsom; Teresa K Woodruff
Journal:  F1000Res       Date:  2020-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.